Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
ACRS — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

11.72

Margin Of Safety %

Put/Call OI Ratio

0.48

EPS Next Q Diff

-1.04

EPS Last/This Y

-0.12

EPS This/Next Y

-0.17

Price

5.91

Target Price

10.64

Analyst Recom

1.17

Performance Q

21.6

Upside

-229.8%

Beta

0.8

Ticker: ACRS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13ACRS5.490.350.8610848
2026-07-14ACRS5.420.350.5010894
2026-07-15ACRS5.610.35999.9910903
2026-07-16ACRS5.370.350.5810913
2026-07-17ACRS5.680.350.0110977
2026-07-20ACRS5.570.360.4210617
2026-07-21ACRS5.680.360.6310683
2026-07-22ACRS5.630.360.0210750
2026-07-23ACRS5.470.362.1410763
2026-07-24ACRS5.230.362.3810780
2026-07-27ACRS5.360.361.4510776
2026-07-28ACRS5.320.370.0010884
2026-07-29ACRS5.120.3710.4310884
2026-07-30ACRS5.320.380.0111004
2026-07-31ACRS5.20.380.0011034
2026-08-03ACRS5.530.380.3711034
2026-08-04ACRS5.980.380.9111099
2026-08-05ACRS6.340.440.2212755
2026-08-07ACRS5.910.481.7213260
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13ACRS5.49-23.1- -0.66
2026-07-14ACRS5.42-23.1- -0.66
2026-07-15ACRS5.61-23.1- -0.66
2026-07-16ACRS5.37-23.1- -0.66
2026-07-17ACRS5.67-23.1- -0.66
2026-07-20ACRS5.57-23.1- -0.66
2026-07-21ACRS5.69-23.1- -0.66
2026-07-22ACRS5.62-23.1- -0.66
2026-07-23ACRS5.48-23.1- -0.66
2026-07-24ACRS5.23-23.1- -0.66
2026-07-27ACRS5.36-23.1- -0.66
2026-07-28ACRS5.32-23.1- -0.66
2026-07-29ACRS5.12-23.1- -0.66
2026-07-30ACRS5.31-23.1- -0.66
2026-07-31ACRS5.20-23.1- -0.66
2026-08-03ACRS5.52-23.1- -0.66
2026-08-04ACRS5.52-23.1- -0.66
2026-08-05ACRS6.35-23.1- -0.66
2026-08-06ACRS6.09-23.1- -0.66
2026-08-07ACRS5.91-23.1- -0.66
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13ACRS-1.1613.2410.00
2026-07-14ACRS-1.1613.2410.00
2026-07-15ACRS-1.1613.2410.00
2026-07-16ACRS-1.1613.2410.00
2026-07-17ACRS-1.1613.2410.00
2026-07-20ACRS-1.1613.2810.00
2026-07-21ACRS-1.1613.2810.00
2026-07-22ACRS-1.1613.2810.00
2026-07-23ACRS-1.1613.2810.00
2026-07-24ACRS-1.1613.2810.00
2026-07-27ACRS-1.1613.2611.72
2026-07-28ACRS-1.1613.2611.72
2026-07-29ACRS-1.1613.2611.72
2026-07-30ACRS-1.1613.2611.72
2026-07-31ACRS-1.1613.2611.72
2026-08-03ACRS-1.1613.3511.72
2026-08-04ACRS-1.1613.3511.72
2026-08-05ACRS-1.1613.3511.72
2026-08-06ACRS-1.1613.3511.72
2026-08-07ACRS-1.1613.3511.72
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.87

Avg. EPS Est. Current Quarter

-0.16

Avg. EPS Est. Next Quarter

-0.17

Insider Transactions

-1.16

Institutional Transactions

13.35

Beta

0.8

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

26

Growth Score

23

Sentiment Score

99

Actual DrawDown %

70.4

Max Drawdown 5-Year %

-96.6

Target Price

10.64

P/E

Forward P/E

PEG

P/S

100.41

P/B

6.63

P/Free Cash Flow

EPS

-0.59

Average EPS Est. Cur. Y​

-0.66

EPS Next Y. (Est.)

-0.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-921.5

Relative Volume

1.34

Return on Equity vs Sector %

-75.8

Return on Equity vs Industry %

-59.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

ACRS Healthcare
$5.91
📉
Swing / Pullback
Buy the dip on strong trends
32 /100
WEAK
Trend
0/20
Pullback
10/25
Volume
3/15
Valuation
8/20
TP/AR
4/10
Options
7/10
RSI
58.1
Range 1M
57.5%
Sup Dist
1%
🚀
Momentum Growth
Ride accelerating trends
N/A
29 /100
WEAK
Momentum
6/25
Growth
6/30
Estimates
2/20
Inst/Vol
11/15
Options
4/10
EPS Yr
-24.7%
EPS NY
-16.8%
52W%
87.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +80% upside
Quality
2/30
Valuation
15/30
Growth
3/25
Stability
8/10
LT Trend
1/5
Upside
+80%
Quality
26
ACRS — P/E HistoricalBiotechnology
Aclaris Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 69
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS

Latest News

Caricamento notizie per ACRS
stock quote shares ACRS – Aclaris Therapeutics Inc Stock Price stock today
news today ACRS – Aclaris Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ACRS – Aclaris Therapeutics Inc yahoo finance google finance
stock history ACRS – Aclaris Therapeutics Inc invest stock market
stock prices ACRS premarket after hours
ticker ACRS fair value insiders trading